<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C0805014-A6FD-41C1-81BE-B94AE4139F25"><gtr:id>C0805014-A6FD-41C1-81BE-B94AE4139F25</gtr:id><gtr:name>Max Planck Society</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FEDCD309-3606-496F-AC21-FAAF0841A417"><gtr:id>FEDCD309-3606-496F-AC21-FAAF0841A417</gtr:id><gtr:name>Clemson University</gtr:name><gtr:address><gtr:line1>Clemson</gtr:line1><gtr:line2>South Carolina</gtr:line2><gtr:line3>29634-0907</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/77C66895-4D42-4105-A4C9-46E246CA4A4B"><gtr:id>77C66895-4D42-4105-A4C9-46E246CA4A4B</gtr:id><gtr:name>University of Auckland</gtr:name><gtr:address><gtr:line1>The University of Auckland</gtr:line1><gtr:line2>Private Bag 92601</gtr:line2><gtr:line3>Symonds Street</gtr:line3><gtr:line4>Auckland</gtr:line4><gtr:postCode>1150</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>New Zealand</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F724BB81-CAD8-43A7-B2C0-394CD9DE4639"><gtr:id>F724BB81-CAD8-43A7-B2C0-394CD9DE4639</gtr:id><gtr:name>University of California, San Diego</gtr:name><gtr:address><gtr:line1>9500 Gilman Drive</gtr:line1><gtr:line4>La Jolla</gtr:line4><gtr:line5>CA 92093</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1F10FB6B-C9C3-4B3B-A91B-AF695129C094"><gtr:id>1F10FB6B-C9C3-4B3B-A91B-AF695129C094</gtr:id><gtr:name>University of Liege</gtr:name><gtr:address><gtr:line1>Place du 20-Aout, 7</gtr:line1><gtr:line4>Liege</gtr:line4><gtr:line5>B-4000</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F20FFE5B-3DA6-4629-894F-4CE13B49B4E4"><gtr:id>F20FFE5B-3DA6-4629-894F-4CE13B49B4E4</gtr:id><gtr:name>Vanderbilt University</gtr:name><gtr:address><gtr:line1>Vanderbilt University</gtr:line1><gtr:line2>2201 West End Avenue</gtr:line2><gtr:line4>Nashville</gtr:line4><gtr:line5>Tennessee</gtr:line5><gtr:postCode>TN 37235</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/FAD72F10-05DD-4B4D-89F4-0475C2A79E10"><gtr:id>FAD72F10-05DD-4B4D-89F4-0475C2A79E10</gtr:id><gtr:name>School of Pharmacy</gtr:name><gtr:department>Pharmacology</gtr:department><gtr:address><gtr:line1>29-39 Brunswick Square</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1N 1AX</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FAD72F10-05DD-4B4D-89F4-0475C2A79E10"><gtr:id>FAD72F10-05DD-4B4D-89F4-0475C2A79E10</gtr:id><gtr:name>School of Pharmacy</gtr:name><gtr:address><gtr:line1>29-39 Brunswick Square</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1N 1AX</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C0805014-A6FD-41C1-81BE-B94AE4139F25"><gtr:id>C0805014-A6FD-41C1-81BE-B94AE4139F25</gtr:id><gtr:name>Max Planck Society</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FEDCD309-3606-496F-AC21-FAAF0841A417"><gtr:id>FEDCD309-3606-496F-AC21-FAAF0841A417</gtr:id><gtr:name>Clemson University</gtr:name><gtr:address><gtr:line1>Clemson</gtr:line1><gtr:line2>South Carolina</gtr:line2><gtr:line3>29634-0907</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/77C66895-4D42-4105-A4C9-46E246CA4A4B"><gtr:id>77C66895-4D42-4105-A4C9-46E246CA4A4B</gtr:id><gtr:name>University of Auckland</gtr:name><gtr:address><gtr:line1>The University of Auckland</gtr:line1><gtr:line2>Private Bag 92601</gtr:line2><gtr:line3>Symonds Street</gtr:line3><gtr:line4>Auckland</gtr:line4><gtr:postCode>1150</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>New Zealand</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F724BB81-CAD8-43A7-B2C0-394CD9DE4639"><gtr:id>F724BB81-CAD8-43A7-B2C0-394CD9DE4639</gtr:id><gtr:name>University of California, San Diego</gtr:name><gtr:address><gtr:line1>9500 Gilman Drive</gtr:line1><gtr:line4>La Jolla</gtr:line4><gtr:line5>CA 92093</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1F10FB6B-C9C3-4B3B-A91B-AF695129C094"><gtr:id>1F10FB6B-C9C3-4B3B-A91B-AF695129C094</gtr:id><gtr:name>University of Liege</gtr:name><gtr:address><gtr:line1>Place du 20-Aout, 7</gtr:line1><gtr:line4>Liege</gtr:line4><gtr:line5>B-4000</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F20FFE5B-3DA6-4629-894F-4CE13B49B4E4"><gtr:id>F20FFE5B-3DA6-4629-894F-4CE13B49B4E4</gtr:id><gtr:name>Vanderbilt University</gtr:name><gtr:address><gtr:line1>Vanderbilt University</gtr:line1><gtr:line2>2201 West End Avenue</gtr:line2><gtr:line4>Nashville</gtr:line4><gtr:line5>Tennessee</gtr:line5><gtr:postCode>TN 37235</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B3503266-26C5-4388-B835-3B426FDEADB5"><gtr:id>B3503266-26C5-4388-B835-3B426FDEADB5</gtr:id><gtr:firstName>Robert</gtr:firstName><gtr:otherNames>Justin</gtr:otherNames><gtr:surname>Harvey</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F9F7EAA9-AEBD-4430-B8DB-CABB16C0D226"><gtr:id>F9F7EAA9-AEBD-4430-B8DB-CABB16C0D226</gtr:id><gtr:firstName>Mark</gtr:firstName><gtr:otherNames>Ian</gtr:otherNames><gtr:surname>Rees</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/359DF4CD-1689-43EE-99B7-469CDF1BBA94"><gtr:id>359DF4CD-1689-43EE-99B7-469CDF1BBA94</gtr:id><gtr:firstName>Kirsten</gtr:firstName><gtr:surname>Harvey</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0601585"><gtr:id>423A3996-B1CE-4A10-9FBE-5A821D3E565C</gtr:id><gtr:title>Dysfunction of GABA and glycine transporters in human neurological disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0601585</gtr:grantReference><gtr:abstractText>The central nervous system is a complex, intricate network of nerve cells (neurones) whose primary function is to transmit and receive messages. This communication occurs at specialised sites of contact known as synapses. At these sites, an arriving nerve impulse causes the release of a chemical (neurotransmitter) from the presynaptic cell which then interacts with receptor molecules embedded in the cell membrane of a neighbouring postsynaptic neurone. Some types of these receptors (e.g. glycine and GABA-A receptors) possess specific ion-permeable channels. The opening of these channels in response to neurotransmitter alters the electrical state of the cell either transmitting or subtly altering the incoming nerve impulse. Neurotransmitters are then recovered from the synapse by transporters located in neighbouring glial cells or the corresponding presynaptic cell. The mechanisms that regulate synaptic transmission and nerve impulse activity are important in understanding normal and diseased states of the brain. Indeed, many drugs in use or under development act primarily via GABA or glycine receptors and their transporters. The therapeutic nature of these agents provides a compelling reason for further understanding the molecular details of the structure and function of these proteins. This proposal will benefit research in this area by enhancing our knowledge concerning transporters for GABA and glycine. In a recent study we were able to show that genetic defects in the glycine transporter GlyT2 were responsible for causing a rare illness called hyperekplexia. This affects newborn children and is characterised by noise or touch-induced seizures which result in breath-holding episodes. In some instances hyperekplexia can lead to brain damage or sudden infant death. Our major aims are: i) to study the consequences of GlyT2 mutations to reveal how these defects disable the transporter, and to investigate whether defects in a glycine transporter found on synaptic vesicles (VIAAT) or proteins that associate with GlyT2 can also cause hyperekplexia; ii) to determine whether genetic mutations in a second glycine transporter, GlyT1, is responsible for cases of a different childhood illness, glycine encephalopathy, which can lead to severe brain damage or death; iii) since defects in GABA receptors are found in some types of epilepsy, we will investigate whether mutations in GABA transporter genes also cause epilepsy. It is our hope that a detailed understanding of the genetic defects responsible for these illnesses will enable better diagnosis and treatment of affected individuals.</gtr:abstractText><gtr:technicalSummary>We have recently proven that a human neurological disorder, hyperekplexia, can be caused by mutations in the gene encoding the presynaptic glycine transporter GlyT2 (Rees et al 2006, Nature Genetics 38:801-806). Prior to this, hyperekplexia was typically associated with mutations in the genes for postsynaptic inhibitory glycine receptor subunits and associated clustering proteins. Having conclusively demonstrated that hyperekplexia can be triggered by presynaptic deficits, this raises the intriguing possibility that presynaptic causes of disease may also exist in related disorders, such as idiopathic generalised epilepsies, where mutations in postsynaptic inhibitory GABA-A receptor subunit genes have already been identified. This programme aims to examine the role of GABA and glycine transporters in hyperekplexia, glycine encephalopathy and idiopathic generalised epilepsies. For glycinergic synapses, we will examine the functional consequences of newly identified GlyT2 hyperekplexia mutations and variants of GlyT2 generated by alternative splicing. We will also perform genetic screening of genes required for presynaptic vesicular packaging of glycine (e.g. the vesicular inhibitory amino acid transporter VIAAT) and two GlyT2 interacting proteins (ULIP-6 and syntenin-1) thought to be important for localisation and turnover of GlyT2. Since knockout mice for a second glycine transporter (GlyT1) show phenotypic similarities to glycine encephalopathy, we will establish whether defects in the human GlyT1 gene underlie this severe disorder. For GABAergic synapses, we will examine genes crucial for GABA vesicular packaging and uptake (i.e. VIAAT and neuronal/glial GABA transporters) in a cohort of ~1000 patients with idiopathic generalised epilepsies. Structural and functional deficits in these proteins will be studied using appropriate cellular models and functional assays (e.g. neurotransmitter uptake assays and electrophysiology). This study will bring together genetic and molecular expertise to define the causes of these neurological disorders, while providing functional insights into inhibitory neurotransmitter transporters.</gtr:technicalSummary><gtr:fund><gtr:end>2011-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>639117</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Vanderbilt University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Neurology</gtr:department><gtr:description>GABA-A receptor gamma2 subunit gene mutations in Dravet syndrome and epilepsy</gtr:description><gtr:id>AC277562-E7FD-4948-B199-A79D565D79BC</gtr:id><gtr:impact>New pathogenic variants in causative genes, leading to feedback to health professionals, patients and carers.</gtr:impact><gtr:outcomeId>XHbeMMq8Aw8-1</gtr:outcomeId><gtr:partnerContribution>Our collaborators will work on in-depth electrophysiology of GABRG2 mutations found in Dravet syndrome and GEFS+ epilepsy</gtr:partnerContribution><gtr:piContribution>While pre-screening genomic DNA samples from Dravet syndrome and GEFS+ epilepsy for analysis in presynaptic GABA transporter genes, we have uncovered likely disease-causing variants in the GABA-A receptor gamma2 subunit gene (GABRG2).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Max Planck Society</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Max Planck Institute for Brain Research</gtr:department><gtr:description>Genetic defects in the RhoGEF collybistin</gtr:description><gtr:id>8481311B-7331-4C9A-82C6-4CF232E27AB9</gtr:id><gtr:impact>These three studies have revealed a pivotal role of collybistin in clustering of gephyrin at selected GABAergic synapses. Mutations in the collybistin gene (ARHGEF9) are now unlikely to represent a significant risk factor for hyperekplexia, but rather produce complex phenotypes in humans, encompassing epilepsy, anxiety, aggression and mental retardation. PubMed IDs: 17690689, 18615734, 19755106.</gtr:impact><gtr:outcomeId>313AF3F7894-1</gtr:outcomeId><gtr:partnerContribution>Our collaborators generated and characterised of a knockout mouse for the RhoGEF collybistin. Our collaborators characterised a balanced chromosomal translocation affecting the human collybistin gene. Our collaborators discovered that neuroligin 2 binds to gephyrin and functions as a specific activator of the RhoGEF collybistin.</gtr:partnerContribution><gtr:piContribution>For these three studies we: i) Generated a targeting construct for the mouse collybistin gene (arhgef9); ii) characterised mis-spliced collybistin mRNAs in a patient cell line that resulted in disruption of gephyrin and GABA-A receptor clustering in cellular and neuronal models; iii) provided data showing that the human ARHGEF9 mutation G55A disrupts neuroligin 2 induction of collybistin-mediated gephyrin clustering.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Auckland</gtr:collaboratingOrganisation><gtr:country>New Zealand</gtr:country><gtr:description>Mapping glycine and GABA-A receptor expression in human brain</gtr:description><gtr:id>B7CE13AC-8B59-4C06-A78D-69385D772EA2</gtr:id><gtr:impact>Collaboration with the New Zealand Neurological Foundation Human Brain Bank, known internationally for the very high quality of formalin-fixed and fresh frozen tissues. These studies have also provided valuable insights into the inhibitory receptor subtypes implicated in hyperekplexia and epilepsy. PubMed IDs: 17444490, 18085588, 19915682, 19950251.</gtr:impact><gtr:outcomeId>36B8EB07A2B-1</gtr:outcomeId><gtr:partnerContribution>Our collaborators provided postmortem human brain tissue from the New Zealand Neurological Foundation Human Brain Bank and expertise and training in immunohistochemistry on human brain sections.</gtr:partnerContribution><gtr:piContribution>Our team provided antibodies against components of inhibitory synapses (e.g. glycine receptors) to enable accurate mapping of inhibitory receptor distributions in human brain.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Max Planck Society</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Max Planck Institute for Experimental Medicine</gtr:department><gtr:description>Genetic defects in the RhoGEF collybistin</gtr:description><gtr:id>5C705161-CB22-49E2-A783-A0BC2AC22EDD</gtr:id><gtr:impact>These three studies have revealed a pivotal role of collybistin in clustering of gephyrin at selected GABAergic synapses. Mutations in the collybistin gene (ARHGEF9) are now unlikely to represent a significant risk factor for hyperekplexia, but rather produce complex phenotypes in humans, encompassing epilepsy, anxiety, aggression and mental retardation. PubMed IDs: 17690689, 18615734, 19755106.</gtr:impact><gtr:outcomeId>313AF3F7894-3</gtr:outcomeId><gtr:partnerContribution>Our collaborators generated and characterised of a knockout mouse for the RhoGEF collybistin. Our collaborators characterised a balanced chromosomal translocation affecting the human collybistin gene. Our collaborators discovered that neuroligin 2 binds to gephyrin and functions as a specific activator of the RhoGEF collybistin.</gtr:partnerContribution><gtr:piContribution>For these three studies we: i) Generated a targeting construct for the mouse collybistin gene (arhgef9); ii) characterised mis-spliced collybistin mRNAs in a patient cell line that resulted in disruption of gephyrin and GABA-A receptor clustering in cellular and neuronal models; iii) provided data showing that the human ARHGEF9 mutation G55A disrupts neuroligin 2 induction of collybistin-mediated gephyrin clustering.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Max Planck Society</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Max Planck Institute for Molecular Cell Biology and Genetics</gtr:department><gtr:description>Genetic defects in the RhoGEF collybistin</gtr:description><gtr:id>4E0B791A-74BD-4BFA-B206-D34369F199E8</gtr:id><gtr:impact>These three studies have revealed a pivotal role of collybistin in clustering of gephyrin at selected GABAergic synapses. Mutations in the collybistin gene (ARHGEF9) are now unlikely to represent a significant risk factor for hyperekplexia, but rather produce complex phenotypes in humans, encompassing epilepsy, anxiety, aggression and mental retardation. PubMed IDs: 17690689, 18615734, 19755106.</gtr:impact><gtr:outcomeId>313AF3F7894-2</gtr:outcomeId><gtr:partnerContribution>Our collaborators generated and characterised of a knockout mouse for the RhoGEF collybistin. Our collaborators characterised a balanced chromosomal translocation affecting the human collybistin gene. Our collaborators discovered that neuroligin 2 binds to gephyrin and functions as a specific activator of the RhoGEF collybistin.</gtr:partnerContribution><gtr:piContribution>For these three studies we: i) Generated a targeting construct for the mouse collybistin gene (arhgef9); ii) characterised mis-spliced collybistin mRNAs in a patient cell line that resulted in disruption of gephyrin and GABA-A receptor clustering in cellular and neuronal models; iii) provided data showing that the human ARHGEF9 mutation G55A disrupts neuroligin 2 induction of collybistin-mediated gephyrin clustering.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of California, San Diego (UCSD)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Pathology</gtr:department><gtr:description>Identification of startle disease genes in dogs</gtr:description><gtr:id>CE24E988-CAD0-4EBA-A26D-965739CC5202</gtr:id><gtr:impact>We demonstrated that a 4.2 kb microdeletion in the glycine transporter GlyT2 gene (SLC6A5) caused startle disease in Irish Wolfhounds (PubMed ID: 21420493) and that a 15.7 kb deletion in BCAN, encoding the brain-specific extracellular matrix proteoglycan brevican, is associated with Episodic Falling Syndrome (PubMed ID: 21821125). These studies have allowed the introduction of diagnostic tests for these disorders via Laboklin (http://www.laboklin.co.uk/), improving animal welfare. The Episodic Falling Syndrome study also represents the first report of a genetic disorder involving a neuronal-specific extracellular matrix proteoglycan. For this reason, BCAN is now a candidate gene for genetic analysis in human disorders with similar clinical presentations, such as startle disease, paroxysmal exercise-induced dyskinesia and episodic ataxia. This collaboration was multidisciplinary, involving genetics and veterinary phenotyping.</gtr:impact><gtr:outcomeId>mJcp83vgWjF-1</gtr:outcomeId><gtr:partnerContribution>Provision of genomic DNA samples for canine startle disease and Episodic Falling Syndrome. Use of SNP arrays to map the physical location of the canine Episodic Falling Syndrome locus and provision of control genomic DNA samples.</gtr:partnerContribution><gtr:piContribution>One aspect of our project was the identification of new genetic causes of startle disease/hyperekplexia. However, sequencing of candidate genes related to presynaptic glycine uptake (VGAT, syntenin-1 and ULIP6) was unproductive. In collaboration with researchers at UCSD and the University of Clemson, examined two unresolved canine disorders with similarity to startle disease. Our contributions to these studies included candidate gene analysis, mapping of microdeletions, breakpoint cloning, Southern blots and MLPA analysis.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Liege</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:description>Glycine transporter defects in cattle</gtr:description><gtr:id>3215EC0E-8E71-4104-8214-ACA1A9137EA1</gtr:id><gtr:impact>Identification of this mutation had an immediate translation into breeding practice, allowing marker-assisted selection against CMD2 by avoiding 'at risk' matings. We have also recently identified CMD2 cases in the UK in collaboration with the Animal Health and Veterinary Laboratories Agency (AHVLA). PubMed IDs: 18344998, 18707791.</gtr:impact><gtr:outcomeId>4E72DF484BB-1</gtr:outcomeId><gtr:partnerContribution>Our collaborators used whole-genome screening approaches to reveal that CMD2 is caused by a missense mutation (T809C) in exon 4 of the glycine transporter GlyT2 gene, resulting in a L270P substitution in the third membrane-spanning domain of GlyT2.</gtr:partnerContribution><gtr:piContribution>Congenital muscular dystonia 2 (CMD2) is a recessive disorder in Belgian Blue cattle that has a severe phenotype, similar to hereditary hyperekplexia in humans, resulting in postnatal death due to respiratory failure. Consistent with the effect of previously characterised missense mutations in human GlyT2, our team found that the L270P substitution did not affect GlyT2 membrane trafficking, but abolished [3H]glycine uptake.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Clemson University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Genetics and Biochemistry</gtr:department><gtr:description>Identification of startle disease genes in dogs</gtr:description><gtr:id>E070EBEE-809A-407E-A371-D491A4A3053A</gtr:id><gtr:impact>We demonstrated that a 4.2 kb microdeletion in the glycine transporter GlyT2 gene (SLC6A5) caused startle disease in Irish Wolfhounds (PubMed ID: 21420493) and that a 15.7 kb deletion in BCAN, encoding the brain-specific extracellular matrix proteoglycan brevican, is associated with Episodic Falling Syndrome (PubMed ID: 21821125). These studies have allowed the introduction of diagnostic tests for these disorders via Laboklin (http://www.laboklin.co.uk/), improving animal welfare. The Episodic Falling Syndrome study also represents the first report of a genetic disorder involving a neuronal-specific extracellular matrix proteoglycan. For this reason, BCAN is now a candidate gene for genetic analysis in human disorders with similar clinical presentations, such as startle disease, paroxysmal exercise-induced dyskinesia and episodic ataxia. This collaboration was multidisciplinary, involving genetics and veterinary phenotyping.</gtr:impact><gtr:outcomeId>mJcp83vgWjF-2</gtr:outcomeId><gtr:partnerContribution>Provision of genomic DNA samples for canine startle disease and Episodic Falling Syndrome. Use of SNP arrays to map the physical location of the canine Episodic Falling Syndrome locus and provision of control genomic DNA samples.</gtr:partnerContribution><gtr:piContribution>One aspect of our project was the identification of new genetic causes of startle disease/hyperekplexia. However, sequencing of candidate genes related to presynaptic glycine uptake (VGAT, syntenin-1 and ULIP6) was unproductive. In collaboration with researchers at UCSD and the University of Clemson, examined two unresolved canine disorders with similarity to startle disease. Our contributions to these studies included candidate gene analysis, mapping of microdeletions, breakpoint cloning, Southern blots and MLPA analysis.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Highlighting MRC-funded research on UCL School of Pharmacy web portal</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>23C63138-4325-454B-AFE7-9BFDA8F7739E</gtr:id><gtr:impact>We have publicised new research findings via the UCL School of Pharmacy web portals, see e.g. http://www.ucl.ac.uk/pharmacy/news/startle

Parents of individuals with hyperekplexia or referring clinicians contacting PIs by E-mail or letter regarding genetic screening.</gtr:impact><gtr:outcomeId>YwLKQJqLuBc</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School of Pharmacy Annual Review</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E371B428-3E37-4251-A3FE-5CF1DDBE529C</gtr:id><gtr:impact>In an article entitled 'Focus on Neuroscience: Genetic research brings new insights into CNS disorders', we reviewed our work on glycine receptors and hyperekplexia in lay language.

Increased awareness of MRC-funded research into glycine receptors and hyperekplexia at the School of Pharmacy and other report recipients.</gtr:impact><gtr:outcomeId>F7D87CFF903</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Brain Awareness Week</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>8C3D7EBB-1301-4FA3-9809-A05E20EA8DCB</gtr:id><gtr:impact>The School of Pharmacy currently hosts the London Chapter of the Society for Neuroscience (http://www.sfnlondonchapter.org/) which organises activities such as annual meetings, seminars and young scientist workshops during Brain Awareness Week, with the aim of engaging and educating a new generation of neuroscientists and raising public awareness and interest in neuroscience research.

Staff and PhD students becoming members of the London Chapter of the Society for Neuroscience.</gtr:impact><gtr:outcomeId>Cs2rP6TvqZe</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Wales Epilepsy Research Network (WERN)</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>6A4C42B7-B983-4BB8-B3E4-93E18C02C5D3</gtr:id><gtr:impact>Additional public engagement activity was undertaken via the Patient Research Development Group (RDG) within the Wales Epilepsy Research Network (WERN). This project was discussed at quarterly meetings involving service users, patient carers, parents of Sudden Unexpected Death in Epilepsy (SUDEP) cases and health professionals involved in epilepsy care. Approximately 30 people are involved in each meeting to discuss how to develop health and social outcomes in biomedical studies, e.g. the impact of genetic diagnosis/explanations.

Increased awareness of potential presynaptic and postsynaptic causes of startle disease/idiopathic epilepsies.</gtr:impact><gtr:outcomeId>daTt4iHfpna</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009,2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Highlighting MRC-funded research on ILS Swansea website</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>47584D00-22B8-4FBA-B9F2-6914AD45D2D2</gtr:id><gtr:impact>MRC-funded research resulting in notable publications or achievements is routinely highlighted on the home page of the ILS Swansea website (http://www.swan.ac.uk/ils/), see e.g. http://www.swan.ac.uk/ils/research/biomed/neuroscienceandmolecularpsychiatry/molecularneuroscience/

Raising awareness of MRC-funded research with the general public, staff, other stakeholders and M.Pharm. students. Parents of individuals with hyperekplexia or referring clinicians contacting PIs by E-mail or letter regarding genetic screening.</gtr:impact><gtr:outcomeId>pXfPcVN9Boi</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007,2008,2009,2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk at the UCL Science Society</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>BDF23F59-B22D-4129-82C2-7DAFCF31CF4B</gtr:id><gtr:impact>Lecture at the UCL Science Society - Defective inhibitory neurotransmission in startle disease: some surprising findings (27th Feb 2014) audience made up of UCL students, staff, alumni and guests.

After talk members of the UCL Science Society made further requests for information about my work and asked to visit my laboratory.</gtr:impact><gtr:outcomeId>545caa8a418df5.62611882</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.ucl.ac.uk/pharmacy/research/disease-models-and-clinical-pharmacology/disease-models-news/ucl-ssl</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk at Caf? Scientifique Event, UCL</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>514CCD3A-4BAD-4061-A9E5-EBD6058A6C33</gtr:id><gtr:impact>Talk on genetics and wellbeing at a Caf&amp;eacute; Scientifique Event, Roberts Building, UCL (19th April 2013) organised through the UCL Public Engagement Unit. The audience consisted of 30 members of the University of The Third Age from North London.

Further invitation to talk at the UCL Science Society (http://www.ucl.ac.uk/science-society/), whose members are drawn from all branches of the Sciences</gtr:impact><gtr:outcomeId>nR6NZkFTEAg</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC Health article</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>45945DC5-6261-4413-A194-5F38EF1A0E16</gtr:id><gtr:impact>Coverage of startle disease research outcomes and new research funding in awareness article on BBC Health website.

Increased awareness of startle disease impacts on affected children and families; Enquiries from scientists, clinicians and members of the public.</gtr:impact><gtr:outcomeId>AbV5qEBuEWG</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.bbc.co.uk/news/health-18911272</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>198520</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Epilepsy Research UK Fellowship</gtr:description><gtr:end>2014-05-02</gtr:end><gtr:fundingOrg>Epilepsy Research UK</gtr:fundingOrg><gtr:id>B573B1CD-127D-4210-A80B-4C70CFF716C7</gtr:id><gtr:outcomeId>THAZnK4k7pE0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1015020</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Project Grant</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G0800498</gtr:fundingRef><gtr:id>53B39B0E-85DF-4761-9184-B5FEC59194FB</gtr:id><gtr:outcomeId>EC1186AB0E30</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>35000</gtr:amountPounds><gtr:country>Norway, Kingdom of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Joint funded PhD studentship/UCL/Uni Research AS Norway</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Uni Research AS</gtr:fundingOrg><gtr:id>4F065050-1248-43A9-BAEF-F668041CC2D2</gtr:id><gtr:outcomeId>MQW2Zu3kfuA0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>98230</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Epilepsy Research UK Project grant</gtr:description><gtr:end>2013-05-02</gtr:end><gtr:fundingOrg>Epilepsy Research UK</gtr:fundingOrg><gtr:id>F1F27AF8-6CCA-4030-B788-2297E86FA44B</gtr:id><gtr:outcomeId>re5a6ZXSwRk0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>81750</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC DTG four-year PhD studentship</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G0800111</gtr:fundingRef><gtr:id>06E01C0F-48A8-4B87-A9CD-F3A4C2603344</gtr:id><gtr:outcomeId>oQMvTVVA24z0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>124835</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Action Medical Research grant</gtr:description><gtr:end>2014-02-02</gtr:end><gtr:fundingOrg>Action Medical Research</gtr:fundingOrg><gtr:fundingRef>1966</gtr:fundingRef><gtr:id>0EF43E92-F6A5-4D34-BC04-9FDB3161FCF4</gtr:id><gtr:outcomeId>gSZX57aJkWQ0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Joint funded PhD studentship/UCL/VU University Amsterdam</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Free University of Amsterdam</gtr:fundingOrg><gtr:id>EC327CCF-F19B-47AA-95BE-BD6EB0776308</gtr:id><gtr:outcomeId>MQW2Zu3kfuA1</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>58020</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>School of Pharmacy</gtr:department><gtr:description>Bloomsbury Colleges PhD studentship/Bloomsbury Consortium</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>University College London</gtr:fundingOrg><gtr:id>14EA34DE-32A8-4150-A989-F3777452BA7A</gtr:id><gtr:outcomeId>RJj4Cnu6eRT0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Genetic tests for canine neurological disorders including startle disease in Irish Wolfhounds and Episodic Falling Syndrome in Cavalier King Charles spaniels. See PubMed IDs: 21420493 and 21821125. These tests have been made available to the general public via commercialisation (UCL Business) with Laboklin Laboratory for Clinical Diagnostics. The Episodic Falling test has been protected under patent EP2522744 (http://www.google.com/patents/EP2522744A1).</gtr:description><gtr:grantRef>G0601585</gtr:grantRef><gtr:id>1C23421A-A267-496E-B776-C382574AA451</gtr:id><gtr:impact>These tests have seen good take-up and have impacted on breeding practices and animal welfare, with the Irish Wolfhound Foundation recently commenting in a letter to the School: 'this is the first clinically useful test for a genetic disease in our breed'. See also awareness articles at: http://www.iwfoundation.org/articles_detail.html?item_id=38&amp;amp;year=2009</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>mZDKWFnSM6h</gtr:outcomeId><gtr:patentId>EP20120167334</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Genetic tests for canine neurological disorders</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>During this study we have recruited a significant number of additional DNA samples from patients with hyperekplexia from clinical referrals. We have also taken receipt of the collaborative idiopathic generalised epilepsy cohorts from Australia, Scotland and London. These are currently being analysed for mutations in GABA transporters.</gtr:description><gtr:id>3C11BECB-CFFD-4A5F-B00C-ECF78E9867FE</gtr:id><gtr:impact>These samples are proving valuable in genetic and structure/function studies and have resulted in additional outputs in 2012 and 2013. See PubMed IDs: 22753417, 22700964, 23184146 and 24108130.</gtr:impact><gtr:outcomeId>7CA8D8D3BF5</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Hyperekplexia/Epilepsy DNA samples</gtr:title><gtr:type>Biological samples</gtr:type><gtr:url>http://europepmc.org/abstract/MED/22753417</gtr:url></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>447CAE34-61A1-478D-A519-30423129B82C</gtr:id><gtr:title>Genetic epilepsy with febrile seizures plus: definite and borderline phenotypes.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/98bd7979d6f9fe98d89895cc8df1c1ba"><gtr:id>98bd7979d6f9fe98d89895cc8df1c1ba</gtr:id><gtr:otherNames>Thomas RH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>pm_12997_27_22147072</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>09716A03-FCA5-416F-8DBF-718A4C743156</gtr:id><gtr:title>The genetics of hyperekplexia: more than startle!</gtr:title><gtr:parentPublicationTitle>Trends in genetics : TIG</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b47875b14997b14297da87096698f11"><gtr:id>5b47875b14997b14297da87096698f11</gtr:id><gtr:otherNames>Harvey RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0168-9525</gtr:issn><gtr:outcomeId>DC49E1C032E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>078BDD9E-2901-4CC1-9DBA-0D2DFEA917FC</gtr:id><gtr:title>Glycine and glycine receptor signalling in non-neuronal cells.</gtr:title><gtr:parentPublicationTitle>Frontiers in molecular neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8bb778ce8386308547c149d712ebfe8"><gtr:id>d8bb778ce8386308547c149d712ebfe8</gtr:id><gtr:otherNames>Van den Eynden J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1662-5099</gtr:issn><gtr:outcomeId>BF656BE63ED</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0E60C374-8071-42F0-ABD1-B89D55DF3386</gtr:id><gtr:title>The genetics of epilepsy--the past, the present and future.</gtr:title><gtr:parentPublicationTitle>Seizure</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2995c86c9ee0e08fabfa1196e5bea202"><gtr:id>2995c86c9ee0e08fabfa1196e5bea202</gtr:id><gtr:otherNames>Rees MI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1059-1311</gtr:issn><gtr:outcomeId>tZN8cjCc6Ci</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2582AD3-8C6A-4021-B67B-9DDAE6F0C9F7</gtr:id><gtr:title>Defective escape behavior in DEAH-box RNA helicase mutants improved by restoring glycine receptor expression.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e6a7b6119ee2f9a0aee514880670869"><gtr:id>0e6a7b6119ee2f9a0aee514880670869</gtr:id><gtr:otherNames>Hirata H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>pm_12997_27_24027265</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD536A02-FF08-4CB5-AD3E-092598925B50</gtr:id><gtr:title>Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Drug discovery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b47875b14997b14297da87096698f11"><gtr:id>5b47875b14997b14297da87096698f11</gtr:id><gtr:otherNames>Harvey RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1474-1776</gtr:issn><gtr:outcomeId>pm_12997_27_24172334</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C6478CD8-226C-4417-806D-5025FD6E86CF</gtr:id><gtr:title>Glycine receptors in the striatum, globus pallidus, and substantia nigra of the human brain: an immunohistochemical study.</gtr:title><gtr:parentPublicationTitle>The Journal of comparative neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7f4d5ab7bd9f291d31e01fbf0e0e45c"><gtr:id>d7f4d5ab7bd9f291d31e01fbf0e0e45c</gtr:id><gtr:otherNames>Waldvogel HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-9967</gtr:issn><gtr:outcomeId>94842965900</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D0C2856-FD1B-4049-9079-AE461393C316</gtr:id><gtr:title>A critical role for glycine transporters in hyperexcitability disorders.</gtr:title><gtr:parentPublicationTitle>Frontiers in molecular neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b47875b14997b14297da87096698f11"><gtr:id>5b47875b14997b14297da87096698f11</gtr:id><gtr:otherNames>Harvey RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1662-5099</gtr:issn><gtr:outcomeId>5B2438B707F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB964C8E-9ADF-4A37-B2E7-2030497C4486</gtr:id><gtr:title>Fine architecture and mutation mapping of human brain inhibitory system ligand gated ion channels by high-throughput homology modeling.</gtr:title><gtr:parentPublicationTitle>Advances in protein chemistry and structural biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/971a636792998c549eb3786fc1268cb1"><gtr:id>971a636792998c549eb3786fc1268cb1</gtr:id><gtr:otherNames>Mullins JG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1876-1623</gtr:issn><gtr:outcomeId>kSzdtEpmhaG</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F65367FA-9B0F-4E98-825A-89EABEEDA8D1</gtr:id><gtr:title>Gephyrin: where do we stand, where do we go?</gtr:title><gtr:parentPublicationTitle>Trends in neurosciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ddc2d6415bfae650d8989a1833ebf32"><gtr:id>5ddc2d6415bfae650d8989a1833ebf32</gtr:id><gtr:otherNames>Fritschy JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0166-2236</gtr:issn><gtr:outcomeId>70E30C77B30</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9325A45A-4E27-4CDC-AEB6-9689A73CE3C5</gtr:id><gtr:title>Differential localization of GABAA receptor subunits within the substantia nigra of the human brain: an immunohistochemical study.</gtr:title><gtr:parentPublicationTitle>The Journal of comparative neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7f4d5ab7bd9f291d31e01fbf0e0e45c"><gtr:id>d7f4d5ab7bd9f291d31e01fbf0e0e45c</gtr:id><gtr:otherNames>Waldvogel HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-9967</gtr:issn><gtr:outcomeId>487A5ACFCFC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E1D34857-D081-478E-BB06-A51688CA09C2</gtr:id><gtr:title>Epilepsy genetics: clinical beginnings and social consequences.</gtr:title><gtr:parentPublicationTitle>QJM : monthly journal of the Association of Physicians</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/59398d9caa5c26797abd412d6a9f5525"><gtr:id>59398d9caa5c26797abd412d6a9f5525</gtr:id><gtr:otherNames>Johnston JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1460-2393</gtr:issn><gtr:outcomeId>EFBBF597282</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>509EE52B-2CA2-48F7-A8DF-39FC1EB9D2CF</gtr:id><gtr:title>Identifying and prioritising epilepsy treatment uncertainties.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/98bd7979d6f9fe98d89895cc8df1c1ba"><gtr:id>98bd7979d6f9fe98d89895cc8df1c1ba</gtr:id><gtr:otherNames>Thomas RH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>LLfoBi6NH6r</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1AD9A548-3468-4D33-A4E9-DE85C7BA64A3</gtr:id><gtr:title>Distinct phenotypes in zebrafish models of human startle disease.</gtr:title><gtr:parentPublicationTitle>Neurobiology of disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/174a7e4cdffd550efe0ce046c1e8b00e"><gtr:id>174a7e4cdffd550efe0ce046c1e8b00e</gtr:id><gtr:otherNames>Ganser LR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0969-9961</gtr:issn><gtr:outcomeId>pm_12997_27_24029548</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>204E906D-4468-42D7-A6F9-55B7FC92BEC2</gtr:id><gtr:title>Plasticity of synaptic inhibition in mouse spinal cord lamina II neurons during early postnatal development and after inactivation of the glycine receptor alpha3 subunit gene.</gtr:title><gtr:parentPublicationTitle>The European journal of neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8ff5a25d4c258ecc94c48af2007562c8"><gtr:id>8ff5a25d4c258ecc94c48af2007562c8</gtr:id><gtr:otherNames>Rajalu M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0953-816X</gtr:issn><gtr:outcomeId>gbDNFNwRExX</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6BA14543-37D6-4E6B-8076-469B79BBF095</gtr:id><gtr:title>GLRB is the third major gene of effect in hyperekplexia.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d36fb27ffa662fffbac9cf91abdeafe0"><gtr:id>d36fb27ffa662fffbac9cf91abdeafe0</gtr:id><gtr:otherNames>Chung SK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_12997_27_23184146</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A6F57234-82A2-4E68-92CA-F29E51DB4152</gtr:id><gtr:title>A novel dominant hyperekplexia mutation Y705C alters trafficking and biochemical properties of the presynaptic glycine transporter GlyT2.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2cd12f1a55a57f1083a5140f432b5ebb"><gtr:id>2cd12f1a55a57f1083a5140f432b5ebb</gtr:id><gtr:otherNames>Gim?nez C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>pm_12997_27_22753417</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D67A8F54-0CFB-46AE-8B9F-2B09219EC41B</gtr:id><gtr:title>Identification of congenital muscular dystonia 2 associated with an inherited GlyT2 defect in Belgian Blue cattle from the United Kingdom.</gtr:title><gtr:parentPublicationTitle>Animal genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11c2457b79282e37fcda0f8a3f1f0f04"><gtr:id>11c2457b79282e37fcda0f8a3f1f0f04</gtr:id><gtr:otherNames>Gill JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0268-9146</gtr:issn><gtr:outcomeId>YtLdYxE4Whi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37D1338B-E9FD-45FB-A3FC-935C70D2BD3E</gtr:id><gtr:title>Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype.</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/04122d7289b96aaee89505cd1a9b2e04"><gtr:id>04122d7289b96aaee89505cd1a9b2e04</gtr:id><gtr:otherNames>McKeon A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>doi_55f98498424c2b7e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>218E04FB-1F4E-415D-858C-133EE00B53FE</gtr:id><gtr:title>Glycinergic transmission: physiological, developmental and pathological implications.</gtr:title><gtr:parentPublicationTitle>Frontiers in molecular neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b47875b14997b14297da87096698f11"><gtr:id>5b47875b14997b14297da87096698f11</gtr:id><gtr:otherNames>Harvey RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1662-5099</gtr:issn><gtr:outcomeId>CXNQ8LWJeci</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B134FAD0-2149-471E-8089-0D55A22D8E6D</gtr:id><gtr:title>Startle disease in Irish wolfhounds associated with a microdeletion in the glycine transporter GlyT2 gene.</gtr:title><gtr:parentPublicationTitle>Neurobiology of disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11c2457b79282e37fcda0f8a3f1f0f04"><gtr:id>11c2457b79282e37fcda0f8a3f1f0f04</gtr:id><gtr:otherNames>Gill JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0969-9961</gtr:issn><gtr:outcomeId>FxTdp5QCFkf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2984B80-DA31-42FB-9DA7-D2C037143026</gtr:id><gtr:title>Novel missense mutations in the glycine receptor ? subunit gene (GLRB) in startle disease.</gtr:title><gtr:parentPublicationTitle>Neurobiology of disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/abc9eb19a243b1960d516b886bb1f552"><gtr:id>abc9eb19a243b1960d516b886bb1f552</gtr:id><gtr:otherNames>James VM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0969-9961</gtr:issn><gtr:outcomeId>545c9a25766371.68387340</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>792AB37F-BC92-4AE4-8911-DEB43F6B52DC</gtr:id><gtr:title>Multifunctional basic motif in the glycine receptor intracellular domain induces subunit-specific sorting.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/183e6ac4be60f8d4616b329497fdfa0f"><gtr:id>183e6ac4be60f8d4616b329497fdfa0f</gtr:id><gtr:otherNames>Melzer N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>CHQ6KWG9mJj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA5A6D71-A4BF-4272-B7AE-6E1C1357D785</gtr:id><gtr:title>A canine BCAN microdeletion associated with episodic falling syndrome.</gtr:title><gtr:parentPublicationTitle>Neurobiology of disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11c2457b79282e37fcda0f8a3f1f0f04"><gtr:id>11c2457b79282e37fcda0f8a3f1f0f04</gtr:id><gtr:otherNames>Gill JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0969-9961</gtr:issn><gtr:outcomeId>hT6g83FNRhg</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E5AC755-53E8-4CA2-8112-8098BBCB00D6</gtr:id><gtr:title>Genotype-phenotype correlations in hyperekplexia: apnoeas, learning difficulties and speech delay.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/98bd7979d6f9fe98d89895cc8df1c1ba"><gtr:id>98bd7979d6f9fe98d89895cc8df1c1ba</gtr:id><gtr:otherNames>Thomas RH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>545c9ce40c2d87.89784928</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A8077FB2-53E3-4C1A-8A74-37003F2CDF59</gtr:id><gtr:title>A balanced chromosomal translocation disrupting ARHGEF9 is associated with epilepsy, anxiety, aggression, and mental retardation.</gtr:title><gtr:parentPublicationTitle>Human mutation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bf78972f5de4dacb7cdfb7477da0301f"><gtr:id>bf78972f5de4dacb7cdfb7477da0301f</gtr:id><gtr:otherNames>Kalscheuer VM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1059-7794</gtr:issn><gtr:outcomeId>423337ABC2D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>923C452F-9477-4A53-9CE6-8DB73FC13823</gtr:id><gtr:title>Impaired GABAergic transmission and altered hippocampal synaptic plasticity in collybistin-deficient mice.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/58113582016cf39d5733b49900ec93bf"><gtr:id>58113582016cf39d5733b49900ec93bf</gtr:id><gtr:otherNames>Papadopoulos T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn><gtr:outcomeId>D2D1747C34B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0880D9A0-AC98-4615-85A9-CC1D3669C753</gtr:id><gtr:title>Scottie cramp and canine epileptoid cramping syndrome in Border terriers.</gtr:title><gtr:parentPublicationTitle>The Veterinary record</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1349e5db547289af59f5a85f5d7acf7"><gtr:id>a1349e5db547289af59f5a85f5d7acf7</gtr:id><gtr:otherNames>Garosi L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0042-4900</gtr:issn><gtr:outcomeId>pm_12997_27_22354655</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC4ADEAF-A9B6-467A-AB56-B4F47A766C88</gtr:id><gtr:title>The conundrum of complexity in epilepsy.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2995c86c9ee0e08fabfa1196e5bea202"><gtr:id>2995c86c9ee0e08fabfa1196e5bea202</gtr:id><gtr:otherNames>Rees MI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>0C7D5E511E9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69BBDB2D-8FB8-4427-B2DA-396FF97FC3DC</gtr:id><gtr:title>Differential localization of gamma-aminobutyric acid type A and glycine receptor subunits and gephyrin in the human pons, medulla oblongata and uppermost cervical segment of the spinal cord: an immunohistochemical study.</gtr:title><gtr:parentPublicationTitle>The Journal of comparative neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7f4d5ab7bd9f291d31e01fbf0e0e45c"><gtr:id>d7f4d5ab7bd9f291d31e01fbf0e0e45c</gtr:id><gtr:otherNames>Waldvogel HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9967</gtr:issn><gtr:outcomeId>E6F803334BE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D691CAE-3E96-4823-A731-7365759C0973</gtr:id><gtr:title>Pathophysiological mechanisms of dominant and recessive GLRA1 mutations in hyperekplexia.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d36fb27ffa662fffbac9cf91abdeafe0"><gtr:id>d36fb27ffa662fffbac9cf91abdeafe0</gtr:id><gtr:otherNames>Chung SK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>KsN5YyvyaGd</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EDFFA58B-0EE6-40AF-97AF-3690E1CED8AA</gtr:id><gtr:title>Neuroligin 2 drives postsynaptic assembly at perisomatic inhibitory synapses through gephyrin and collybistin.</gtr:title><gtr:parentPublicationTitle>Neuron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50b0bf9255d227dc314387aa7edf0def"><gtr:id>50b0bf9255d227dc314387aa7edf0def</gtr:id><gtr:otherNames>Poulopoulos A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0896-6273</gtr:issn><gtr:outcomeId>12C25C41423</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E583C566-F203-429A-ACD1-0AD88549CED2</gtr:id><gtr:title>Mutations in the GlyT2 gene (SLC6A5) are a second major cause of startle disease.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e8b29e71535f299a85bb5dfa2c647e4f"><gtr:id>e8b29e71535f299a85bb5dfa2c647e4f</gtr:id><gtr:otherNames>Carta E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>pm_12997_27_22700964</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89275439-6FBF-4A38-904D-71C28C3F7465</gtr:id><gtr:title>Highly effective SNP-based association mapping and management of recessive defects in livestock.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e47282c318c4d7b0835c9e63b232cdc"><gtr:id>8e47282c318c4d7b0835c9e63b232cdc</gtr:id><gtr:otherNames>Charlier C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>CB64A597BC9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>154D2720-1159-499D-9352-F7B26F4A4C1C</gtr:id><gtr:title>Molecular mechanisms of glycine transporter GlyT2 mutations in startle disease.</gtr:title><gtr:parentPublicationTitle>Biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/abc9eb19a243b1960d516b886bb1f552"><gtr:id>abc9eb19a243b1960d516b886bb1f552</gtr:id><gtr:otherNames>James VM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1431-6730</gtr:issn><gtr:outcomeId>i7f3fwDufwr</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C826640F-BFC4-4C6D-8A4B-3F9393F33A22</gtr:id><gtr:title>Hyperekplexia: Stiffness, startle and syncope</gtr:title><gtr:parentPublicationTitle>Journal of Pediatric Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/013f17d4f8fca6640cff6774a592320e"><gtr:id>013f17d4f8fca6640cff6774a592320e</gtr:id><gtr:otherNames>Rees M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>hMgQ3RkYiYE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2DCF43EE-95E3-4E26-8843-5B6FA70CFD60</gtr:id><gtr:title>Frontiers in molecular neuroscience - r&amp;eacute;sum&amp;eacute; and perspective.</gtr:title><gtr:parentPublicationTitle>Frontiers in molecular neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d485d5538b9736a4445f38d0f15d51c"><gtr:id>8d485d5538b9736a4445f38d0f15d51c</gtr:id><gtr:otherNames>Meier JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1662-5099</gtr:issn><gtr:outcomeId>pm_12997_27_22232574</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A7DE15B-9509-4BF7-A7AE-2D22C3E0AFEF</gtr:id><gtr:title>Implications for families of advances in understanding the genetic basis of epilepsy.</gtr:title><gtr:parentPublicationTitle>Seizure</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6bb6439844a9a78ed661f93dc147a49"><gtr:id>d6bb6439844a9a78ed661f93dc147a49</gtr:id><gtr:otherNames>Hammond CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1059-1311</gtr:issn><gtr:outcomeId>R6Cxa2DcrjE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>536DE67C-9982-4898-85E0-DD37BA67ED36</gtr:id><gtr:title>The glycinergic system in human startle disease: a genetic screening approach.</gtr:title><gtr:parentPublicationTitle>Frontiers in molecular neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9bcc1f480be263e2ee8d0862f3aa325d"><gtr:id>9bcc1f480be263e2ee8d0862f3aa325d</gtr:id><gtr:otherNames>Davies JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1662-5099</gtr:issn><gtr:outcomeId>jeXZksJkBgw</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D3A0F1E-4BF2-4919-A974-712971DB8B72</gtr:id><gtr:title>Localization of glycine receptors in the human forebrain, brainstem, and cervical spinal cord: an immunohistochemical review.</gtr:title><gtr:parentPublicationTitle>Frontiers in molecular neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90214f68d0542f77eb5ed27b9c63d5f3"><gtr:id>90214f68d0542f77eb5ed27b9c63d5f3</gtr:id><gtr:otherNames>Baer K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1662-5099</gtr:issn><gtr:outcomeId>1F63183001F</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0601585</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>